About 2 results

Dr. Audrey Odom John (Washington University in St. Louis) and Dr. Cynthia Dowd (The George Washington University) identified an antimalarial drug candidate with a novel, parasite-specific target. The investigators have explored various solutions to improve the compound’s pharmacokinetic properties, including administration in a patch formulation. BVGH coordinated a call between Dr. Odom John, Dr. Dowd, and a Pfizer scientist with expertise in transdermal drug delivery to help assess the feasibility of this approach for the compound.

A Pfizer scientist with expertise in transdermal drug delivery shared advice on the feasibility of a transdermal delivery for the investigators’ antimalarial drug candidate and helped suggest next steps for development.

It is estimated that one quarter of the world’s population is infected with tuberculosis (TB). To deter the growing threat of multidrug-resistant tuberculosis, new treatments are needed to successfully reduce the global burden of this disease. Dr. Cynthia Dowd from The George Washington University (GW) has developed lead compounds with anti-tubercular activity, wich could be promising candidates for TB drug development. In order to assist Dr. Dowd in target identification, MSD will be screening these compounds to determine their activity against a specific Mycobacterium tuberculosis target.